Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA ® (pembrolizumab)

Dateline City: WILMINGTON, Del.& KENILWORTH, N.J.Clinical Program Now Includes Seven Registrational Trials Across Five Tumor TypesWILMINGTON, Del.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck ’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).Language: Englishread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news